nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—KIT—testicular cancer	0.46	1	CbGaD
Nilotinib—UGT1A1—Etoposide—testicular cancer	0.0249	0.104	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—testicular cancer	0.0243	0.101	CbGbCtD
Nilotinib—CYP2B6—Ifosfamide—testicular cancer	0.0202	0.084	CbGbCtD
Nilotinib—ABCG2—Carboplatin—testicular cancer	0.0163	0.068	CbGbCtD
Nilotinib—CYP2C8—Ifosfamide—testicular cancer	0.0153	0.0636	CbGbCtD
Nilotinib—ABCG2—Cisplatin—testicular cancer	0.014	0.0581	CbGbCtD
Nilotinib—ABCG2—Etoposide—testicular cancer	0.0137	0.0571	CbGbCtD
Nilotinib—CYP2C9—Ifosfamide—testicular cancer	0.0107	0.0444	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—testicular cancer	0.00982	0.0408	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—testicular cancer	0.00935	0.0389	CbGbCtD
Nilotinib—ABCG2—Methotrexate—testicular cancer	0.00906	0.0377	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—testicular cancer	0.00876	0.0365	CbGbCtD
Nilotinib—CYP2C8—Etoposide—testicular cancer	0.0073	0.0304	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—testicular cancer	0.00658	0.0274	CbGbCtD
Nilotinib—CYP3A4—Ifosfamide—testicular cancer	0.0062	0.0258	CbGbCtD
Nilotinib—ABCB1—Vinblastine—testicular cancer	0.00549	0.0228	CbGbCtD
Nilotinib—KIT—seminiferous tubule of testis—testicular cancer	0.00532	0.0684	CbGeAlD
Nilotinib—CYP2C9—Cisplatin—testicular cancer	0.00519	0.0216	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—testicular cancer	0.00517	0.0215	CbGbCtD
Nilotinib—ABCB1—Cisplatin—testicular cancer	0.00503	0.0209	CbGbCtD
Nilotinib—ABCB1—Etoposide—testicular cancer	0.00494	0.0206	CbGbCtD
Nilotinib—Ponatinib—FGFR3—testicular cancer	0.0037	0.58	CrCbGaD
Nilotinib—ABCB1—Doxorubicin—testicular cancer	0.00337	0.014	CbGbCtD
Nilotinib—CYP3A4—Vinblastine—testicular cancer	0.00329	0.0137	CbGbCtD
Nilotinib—ABCB1—Methotrexate—testicular cancer	0.00327	0.0136	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—testicular cancer	0.00318	0.0132	CbGbCtD
Nilotinib—CYP3A4—Etoposide—testicular cancer	0.00296	0.0123	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—testicular cancer	0.00202	0.00841	CbGbCtD
Nilotinib—Ponatinib—KIT—testicular cancer	0.00166	0.26	CrCbGaD
Nilotinib—MAPK8—embryo—testicular cancer	0.00159	0.0205	CbGeAlD
Nilotinib—FRK—gonad—testicular cancer	0.00142	0.0182	CbGeAlD
Nilotinib—EPHB3—embryo—testicular cancer	0.00131	0.0169	CbGeAlD
Nilotinib—CDC42BPB—gonad—testicular cancer	0.00119	0.0154	CbGeAlD
Nilotinib—HCK—seminal vesicle—testicular cancer	0.00113	0.0146	CbGeAlD
Nilotinib—EPHA4—embryo—testicular cancer	0.0011	0.0141	CbGeAlD
Nilotinib—MAPK8—gonad—testicular cancer	0.00108	0.0139	CbGeAlD
Nilotinib—EPHA6—gonad—testicular cancer	0.00108	0.0139	CbGeAlD
Nilotinib—Imatinib—KIT—testicular cancer	0.00102	0.16	CrCbGaD
Nilotinib—FRK—testis—testicular cancer	0.00102	0.0131	CbGeAlD
Nilotinib—MAPK14—embryo—testicular cancer	0.00101	0.013	CbGeAlD
Nilotinib—FGR—embryo—testicular cancer	0.00101	0.0129	CbGeAlD
Nilotinib—MAPK11—female gonad—testicular cancer	0.000978	0.0126	CbGeAlD
Nilotinib—CDC42BPB—female gonad—testicular cancer	0.00097	0.0125	CbGeAlD
Nilotinib—FGR—seminal vesicle—testicular cancer	0.000945	0.0122	CbGeAlD
Nilotinib—EPHA8—testis—testicular cancer	0.000933	0.012	CbGeAlD
Nilotinib—CA14—seminal vesicle—testicular cancer	0.000923	0.0119	CbGeAlD
Nilotinib—TEK—embryo—testicular cancer	0.000917	0.0118	CbGeAlD
Nilotinib—EPHB4—seminal vesicle—testicular cancer	0.0009	0.0116	CbGeAlD
Nilotinib—EPHA2—seminal vesicle—testicular cancer	0.000882	0.0114	CbGeAlD
Nilotinib—MAPK8—female gonad—testicular cancer	0.000877	0.0113	CbGeAlD
Nilotinib—MAPK11—testis—testicular cancer	0.000868	0.0112	CbGeAlD
Nilotinib—CDC42BPB—testis—testicular cancer	0.00086	0.0111	CbGeAlD
Nilotinib—PDGFRA—embryo—testicular cancer	0.00083	0.0107	CbGeAlD
Nilotinib—EPHB6—seminal vesicle—testicular cancer	0.000823	0.0106	CbGeAlD
Nilotinib—EPHA3—testis—testicular cancer	0.000816	0.0105	CbGeAlD
Nilotinib—MAPK8—testis—testicular cancer	0.000778	0.01	CbGeAlD
Nilotinib—EPHA6—testis—testicular cancer	0.000778	0.01	CbGeAlD
Nilotinib—TIE1—female gonad—testicular cancer	0.000761	0.00979	CbGeAlD
Nilotinib—EPHA4—gonad—testicular cancer	0.000744	0.00957	CbGeAlD
Nilotinib—CSF1R—embryo—testicular cancer	0.000731	0.00941	CbGeAlD
Nilotinib—BRAF—female gonad—testicular cancer	0.000729	0.00938	CbGeAlD
Nilotinib—EPHB3—female gonad—testicular cancer	0.000724	0.00931	CbGeAlD
Nilotinib—BLK—lymph node—testicular cancer	0.000714	0.00918	CbGeAlD
Nilotinib—MAP4K1—testis—testicular cancer	0.000707	0.0091	CbGeAlD
Nilotinib—MAP2K5—seminal vesicle—testicular cancer	0.000704	0.00905	CbGeAlD
Nilotinib—CSF1R—seminal vesicle—testicular cancer	0.000687	0.00883	CbGeAlD
Nilotinib—TIE1—testis—testicular cancer	0.000675	0.00868	CbGeAlD
Nilotinib—HCK—female gonad—testicular cancer	0.000665	0.00855	CbGeAlD
Nilotinib—KIT—embryo—testicular cancer	0.000664	0.00854	CbGeAlD
Nilotinib—ABL2—female gonad—testicular cancer	0.000661	0.0085	CbGeAlD
Nilotinib—PDGFRB—embryo—testicular cancer	0.000648	0.00834	CbGeAlD
Nilotinib—BRAF—testis—testicular cancer	0.000647	0.00832	CbGeAlD
Nilotinib—EPHB3—testis—testicular cancer	0.000642	0.00826	CbGeAlD
Nilotinib—MAPK11—lymph node—testicular cancer	0.000629	0.00809	CbGeAlD
Nilotinib—CDC42BPB—lymph node—testicular cancer	0.000624	0.00802	CbGeAlD
Nilotinib—KIT—seminal vesicle—testicular cancer	0.000623	0.00802	CbGeAlD
Nilotinib—PDGFRB—seminal vesicle—testicular cancer	0.000609	0.00783	CbGeAlD
Nilotinib—EPHA4—female gonad—testicular cancer	0.000604	0.00778	CbGeAlD
Nilotinib—EPHA3—lymph node—testicular cancer	0.000591	0.00761	CbGeAlD
Nilotinib—HCK—testis—testicular cancer	0.00059	0.00759	CbGeAlD
Nilotinib—ABL2—testis—testicular cancer	0.000586	0.00754	CbGeAlD
Nilotinib—ABL1—embryo—testicular cancer	0.000578	0.00743	CbGeAlD
Nilotinib—MAPK8—lymph node—testicular cancer	0.000564	0.00726	CbGeAlD
Nilotinib—PDGFRA—gonad—testicular cancer	0.000564	0.00725	CbGeAlD
Nilotinib—MAPK14—female gonad—testicular cancer	0.000557	0.00717	CbGeAlD
Nilotinib—LCK—female gonad—testicular cancer	0.000555	0.00714	CbGeAlD
Nilotinib—FGR—female gonad—testicular cancer	0.000555	0.00714	CbGeAlD
Nilotinib—ABL1—seminal vesicle—testicular cancer	0.000543	0.00698	CbGeAlD
Nilotinib—EPHA4—testis—testicular cancer	0.000536	0.0069	CbGeAlD
Nilotinib—CA3—testis—testicular cancer	0.000529	0.00681	CbGeAlD
Nilotinib—EPHB4—female gonad—testicular cancer	0.000528	0.0068	CbGeAlD
Nilotinib—EPHA2—female gonad—testicular cancer	0.000518	0.00667	CbGeAlD
Nilotinib—MAP4K1—lymph node—testicular cancer	0.000513	0.0066	CbGeAlD
Nilotinib—CA9—testis—testicular cancer	0.000507	0.00652	CbGeAlD
Nilotinib—TEK—female gonad—testicular cancer	0.000506	0.0065	CbGeAlD
Nilotinib—CSF1R—gonad—testicular cancer	0.000496	0.00638	CbGeAlD
Nilotinib—MAPK14—testis—testicular cancer	0.000494	0.00636	CbGeAlD
Nilotinib—FGR—testis—testicular cancer	0.000492	0.00633	CbGeAlD
Nilotinib—LCK—testis—testicular cancer	0.000492	0.00633	CbGeAlD
Nilotinib—TIE1—lymph node—testicular cancer	0.000489	0.00629	CbGeAlD
Nilotinib—EPHB6—female gonad—testicular cancer	0.000483	0.00622	CbGeAlD
Nilotinib—BRAF—lymph node—testicular cancer	0.000469	0.00603	CbGeAlD
Nilotinib—EPHB4—testis—testicular cancer	0.000469	0.00603	CbGeAlD
Nilotinib—EPHB3—lymph node—testicular cancer	0.000465	0.00598	CbGeAlD
Nilotinib—EPHA2—testis—testicular cancer	0.00046	0.00591	CbGeAlD
Nilotinib—PDGFRA—female gonad—testicular cancer	0.000458	0.00589	CbGeAlD
Nilotinib—KIT—gonad—testicular cancer	0.000451	0.0058	CbGeAlD
Nilotinib—TEK—testis—testicular cancer	0.000448	0.00577	CbGeAlD
Nilotinib—CA4—seminal vesicle—testicular cancer	0.000446	0.00573	CbGeAlD
Nilotinib—PDGFRB—gonad—testicular cancer	0.00044	0.00566	CbGeAlD
Nilotinib—EPHB6—testis—testicular cancer	0.000428	0.00551	CbGeAlD
Nilotinib—HCK—lymph node—testicular cancer	0.000427	0.0055	CbGeAlD
Nilotinib—ABL2—lymph node—testicular cancer	0.000425	0.00547	CbGeAlD
Nilotinib—MAP2K5—female gonad—testicular cancer	0.000413	0.00532	CbGeAlD
Nilotinib—PDGFRA—testis—testicular cancer	0.000406	0.00523	CbGeAlD
Nilotinib—CSF1R—female gonad—testicular cancer	0.000403	0.00519	CbGeAlD
Nilotinib—CA2—embryo—testicular cancer	0.000393	0.00506	CbGeAlD
Nilotinib—ABL1—gonad—testicular cancer	0.000392	0.00505	CbGeAlD
Nilotinib—EPHA4—lymph node—testicular cancer	0.000389	0.005	CbGeAlD
Nilotinib—CA3—lymph node—testicular cancer	0.000384	0.00494	CbGeAlD
Nilotinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000382	0.173	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000382	0.173	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000382	0.173	CbGdCrCtD
Nilotinib—CA2—seminal vesicle—testicular cancer	0.00037	0.00476	CbGeAlD
Nilotinib—MAP2K5—testis—testicular cancer	0.000366	0.00471	CbGeAlD
Nilotinib—KIT—female gonad—testicular cancer	0.000366	0.00471	CbGeAlD
Nilotinib—MAPK14—lymph node—testicular cancer	0.000358	0.00461	CbGeAlD
Nilotinib—CSF1R—testis—testicular cancer	0.000358	0.0046	CbGeAlD
Nilotinib—PDGFRB—female gonad—testicular cancer	0.000358	0.0046	CbGeAlD
Nilotinib—FGR—lymph node—testicular cancer	0.000357	0.00459	CbGeAlD
Nilotinib—LCK—lymph node—testicular cancer	0.000357	0.00459	CbGeAlD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000354	0.16	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000354	0.16	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000354	0.16	CbGdCrCtD
Nilotinib—ABCG2—seminal vesicle—testicular cancer	0.000342	0.0044	CbGeAlD
Nilotinib—EPHB4—lymph node—testicular cancer	0.00034	0.00437	CbGeAlD
Nilotinib—EPHA2—lymph node—testicular cancer	0.000333	0.00429	CbGeAlD
Nilotinib—TEK—lymph node—testicular cancer	0.000325	0.00418	CbGeAlD
Nilotinib—KIT—testis—testicular cancer	0.000325	0.00418	CbGeAlD
Nilotinib—ABL1—female gonad—testicular cancer	0.000319	0.0041	CbGeAlD
Nilotinib—PDGFRB—testis—testicular cancer	0.000317	0.00408	CbGeAlD
Nilotinib—EPHB6—lymph node—testicular cancer	0.000311	0.004	CbGeAlD
Nilotinib—PDGFRA—lymph node—testicular cancer	0.000294	0.00379	CbGeAlD
Nilotinib—ABL1—testis—testicular cancer	0.000283	0.00364	CbGeAlD
Nilotinib—MAP2K5—lymph node—testicular cancer	0.000266	0.00342	CbGeAlD
Nilotinib—CA4—female gonad—testicular cancer	0.000262	0.00337	CbGeAlD
Nilotinib—CSF1R—lymph node—testicular cancer	0.000259	0.00334	CbGeAlD
Nilotinib—KIT—lymph node—testicular cancer	0.000235	0.00303	CbGeAlD
Nilotinib—CA4—testis—testicular cancer	0.000232	0.00299	CbGeAlD
Nilotinib—PDGFRB—lymph node—testicular cancer	0.00023	0.00296	CbGeAlD
Nilotinib—CYP2B6—gonad—testicular cancer	0.000228	0.00294	CbGeAlD
Nilotinib—CA2—female gonad—testicular cancer	0.000217	0.00279	CbGeAlD
Nilotinib—CA1—lymph node—testicular cancer	0.000215	0.00277	CbGeAlD
Nilotinib—ABL1—lymph node—testicular cancer	0.000205	0.00264	CbGeAlD
Nilotinib—ABCG2—female gonad—testicular cancer	0.000201	0.00259	CbGeAlD
Nilotinib—CA2—testis—testicular cancer	0.000192	0.00248	CbGeAlD
Nilotinib—CYP2C8—testis—testicular cancer	0.000183	0.00236	CbGeAlD
Nilotinib—ABCB1—embryo—testicular cancer	0.00018	0.00231	CbGeAlD
Nilotinib—ABCG2—testis—testicular cancer	0.000178	0.00229	CbGeAlD
Nilotinib—ABCB1—seminal vesicle—testicular cancer	0.000169	0.00217	CbGeAlD
Nilotinib—CA4—lymph node—testicular cancer	0.000168	0.00216	CbGeAlD
Nilotinib—CYP2B6—testis—testicular cancer	0.000164	0.00212	CbGeAlD
Nilotinib—CA2—lymph node—testicular cancer	0.00014	0.0018	CbGeAlD
Nilotinib—CYP2D6—female gonad—testicular cancer	0.000138	0.00177	CbGeAlD
Nilotinib—ABCG2—lymph node—testicular cancer	0.000129	0.00166	CbGeAlD
Nilotinib—CYP2D6—testis—testicular cancer	0.000122	0.00157	CbGeAlD
Nilotinib—ABCB1—gonad—testicular cancer	0.000122	0.00157	CbGeAlD
Nilotinib—ABCB1—female gonad—testicular cancer	9.91e-05	0.00128	CbGeAlD
Nilotinib—ABCB1—testis—testicular cancer	8.79e-05	0.00113	CbGeAlD
Nilotinib—ABCB1—lymph node—testicular cancer	6.37e-05	0.00082	CbGeAlD
Nilotinib—Haemoglobin—Epirubicin—testicular cancer	5.65e-05	0.00042	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—testicular cancer	5.65e-05	0.00042	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—testicular cancer	5.65e-05	0.00042	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—testicular cancer	5.64e-05	0.000419	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—testicular cancer	5.64e-05	0.000419	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—testicular cancer	5.64e-05	0.000419	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—testicular cancer	5.64e-05	0.000419	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—testicular cancer	5.64e-05	0.000419	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—testicular cancer	5.63e-05	0.000418	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—testicular cancer	5.63e-05	0.000418	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—testicular cancer	5.62e-05	0.000417	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—testicular cancer	5.6e-05	0.000417	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—testicular cancer	5.6e-05	0.000416	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—testicular cancer	5.58e-05	0.000415	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—testicular cancer	5.58e-05	0.000415	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—testicular cancer	5.58e-05	0.000415	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—testicular cancer	5.56e-05	0.000413	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—testicular cancer	5.54e-05	0.000412	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—testicular cancer	5.53e-05	0.000411	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—testicular cancer	5.53e-05	0.000411	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—testicular cancer	5.51e-05	0.00041	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—testicular cancer	5.48e-05	0.000408	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—testicular cancer	5.47e-05	0.000406	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—testicular cancer	5.45e-05	0.000405	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—testicular cancer	5.43e-05	0.000404	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—testicular cancer	5.42e-05	0.000403	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—testicular cancer	5.42e-05	0.000403	CcSEcCtD
Nilotinib—Chills—Methotrexate—testicular cancer	5.39e-05	0.000401	CcSEcCtD
Nilotinib—Nausea—Ifosfamide—testicular cancer	5.36e-05	0.000399	CcSEcCtD
Nilotinib—Diarrhoea—Cisplatin—testicular cancer	5.33e-05	0.000396	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—testicular cancer	5.32e-05	0.000395	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—testicular cancer	5.31e-05	0.000395	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—testicular cancer	5.3e-05	0.000394	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—testicular cancer	5.27e-05	0.000391	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—testicular cancer	5.26e-05	0.000391	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—testicular cancer	5.25e-05	0.00039	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—testicular cancer	5.25e-05	0.00039	CcSEcCtD
Nilotinib—Erythema—Methotrexate—testicular cancer	5.23e-05	0.000389	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—testicular cancer	5.23e-05	0.000389	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—testicular cancer	5.23e-05	0.000389	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—testicular cancer	5.22e-05	0.000388	CcSEcCtD
Nilotinib—Flushing—Epirubicin—testicular cancer	5.22e-05	0.000388	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—testicular cancer	5.22e-05	0.000388	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—testicular cancer	5.21e-05	0.000387	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—testicular cancer	5.21e-05	0.000387	CcSEcCtD
Nilotinib—BLK—Adaptive Immune System—KITLG—testicular cancer	5.18e-05	0.000661	CbGpPWpGaD
Nilotinib—Hypoaesthesia—Doxorubicin—testicular cancer	5.18e-05	0.000385	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—testicular cancer	5.17e-05	0.000384	CcSEcCtD
Nilotinib—LYN—Adaptive Immune System—BCL10—testicular cancer	5.15e-05	0.000657	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—KIT—testicular cancer	5.14e-05	0.000656	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	5.14e-05	0.000656	CbGpPWpGaD
Nilotinib—Urinary tract disorder—Doxorubicin—testicular cancer	5.14e-05	0.000382	CcSEcCtD
Nilotinib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	5.13e-05	0.000654	CbGpPWpGaD
Nilotinib—Oedema peripheral—Doxorubicin—testicular cancer	5.13e-05	0.000381	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—testicular cancer	5.12e-05	0.000381	CcSEcCtD
Nilotinib—Asthenia—Etoposide—testicular cancer	5.12e-05	0.00038	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—testicular cancer	5.12e-05	0.00038	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—testicular cancer	5.1e-05	0.000379	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—testicular cancer	5.1e-05	0.000379	CcSEcCtD
Nilotinib—BRAF—Signaling by NGF—KIT—testicular cancer	5.09e-05	0.00065	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—BCL10—testicular cancer	5.09e-05	0.000649	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	5.08e-05	0.000648	CbGpPWpGaD
Nilotinib—Immune system disorder—Epirubicin—testicular cancer	5.08e-05	0.000378	CcSEcCtD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	5.07e-05	0.000647	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—FGFR3—testicular cancer	5.07e-05	0.000647	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—FGFR3—testicular cancer	5.07e-05	0.000647	CbGpPWpGaD
Nilotinib—Mediastinal disorder—Epirubicin—testicular cancer	5.07e-05	0.000377	CcSEcCtD
Nilotinib—Back pain—Methotrexate—testicular cancer	5.06e-05	0.000376	CcSEcCtD
Nilotinib—KIT—Signaling by NGF—FGFR3—testicular cancer	5.05e-05	0.000644	CbGpPWpGaD
Nilotinib—Chills—Epirubicin—testicular cancer	5.05e-05	0.000375	CcSEcCtD
Nilotinib—Pruritus—Etoposide—testicular cancer	5.04e-05	0.000375	CcSEcCtD
Nilotinib—LCK—Signaling by EGFR—FGFR3—testicular cancer	5.03e-05	0.000641	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—KIT—testicular cancer	5.03e-05	0.000641	CbGpPWpGaD
Nilotinib—Arrhythmia—Epirubicin—testicular cancer	5.03e-05	0.000373	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—testicular cancer	5.02e-05	0.000373	CcSEcCtD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5e-05	0.000638	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—KIT—testicular cancer	5e-05	0.000638	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—FGFR3—testicular cancer	4.98e-05	0.000636	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—KIT—testicular cancer	4.98e-05	0.000635	CbGpPWpGaD
Nilotinib—Alopecia—Epirubicin—testicular cancer	4.97e-05	0.000369	CcSEcCtD
Nilotinib—LCK—Signaling by PDGF—FGFR3—testicular cancer	4.96e-05	0.000633	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—INSL3—testicular cancer	4.96e-05	0.000632	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—KIT—testicular cancer	4.95e-05	0.000632	CbGpPWpGaD
Nilotinib—Vomiting—Cisplatin—testicular cancer	4.95e-05	0.000368	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—testicular cancer	4.93e-05	0.000367	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—testicular cancer	4.93e-05	0.000366	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—testicular cancer	4.92e-05	0.000366	CcSEcCtD
Nilotinib—Rash—Cisplatin—testicular cancer	4.91e-05	0.000365	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—testicular cancer	4.9e-05	0.000364	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—testicular cancer	4.9e-05	0.000364	CcSEcCtD
Nilotinib—Erythema—Epirubicin—testicular cancer	4.9e-05	0.000364	CcSEcCtD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	4.88e-05	0.000623	CbGpPWpGaD
Nilotinib—Diarrhoea—Etoposide—testicular cancer	4.88e-05	0.000363	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—testicular cancer	4.86e-05	0.000362	CcSEcCtD
Nilotinib—EPHA2—Developmental Biology—MMP2—testicular cancer	4.86e-05	0.00062	CbGpPWpGaD
Nilotinib—Ill-defined disorder—Methotrexate—testicular cancer	4.86e-05	0.000361	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—testicular cancer	4.85e-05	0.000361	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—testicular cancer	4.84e-05	0.000359	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—testicular cancer	4.83e-05	0.000359	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—testicular cancer	4.83e-05	0.000359	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—testicular cancer	4.83e-05	0.000359	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—testicular cancer	4.8e-05	0.000356	CcSEcCtD
Nilotinib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	4.78e-05	0.00061	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	4.77e-05	0.000609	CbGpPWpGaD
Nilotinib—Back pain—Epirubicin—testicular cancer	4.74e-05	0.000352	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—testicular cancer	4.72e-05	0.000351	CcSEcCtD
Nilotinib—Malaise—Methotrexate—testicular cancer	4.72e-05	0.000351	CcSEcCtD
Nilotinib—Dizziness—Etoposide—testicular cancer	4.72e-05	0.00035	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—testicular cancer	4.71e-05	0.00035	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—testicular cancer	4.7e-05	0.000349	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—testicular cancer	4.7e-05	0.000349	CcSEcCtD
Nilotinib—LCK—B Cell Activation—FGFR3—testicular cancer	4.7e-05	0.000599	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	4.69e-05	0.000598	CbGpPWpGaD
Nilotinib—Mediastinal disorder—Doxorubicin—testicular cancer	4.69e-05	0.000349	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—testicular cancer	4.68e-05	0.000348	CcSEcCtD
Nilotinib—Chills—Doxorubicin—testicular cancer	4.67e-05	0.000347	CcSEcCtD
Nilotinib—LCK—Signaling by FGFR in disease—KIT—testicular cancer	4.66e-05	0.000594	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	4.66e-05	0.000594	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—KIT—testicular cancer	4.66e-05	0.000594	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—KITLG—testicular cancer	4.65e-05	0.000593	CbGpPWpGaD
Nilotinib—Arrhythmia—Doxorubicin—testicular cancer	4.65e-05	0.000346	CcSEcCtD
Nilotinib—Nausea—Cisplatin—testicular cancer	4.62e-05	0.000344	CcSEcCtD
Nilotinib—LCK—Signaling by EGFR—KIT—testicular cancer	4.62e-05	0.000589	CbGpPWpGaD
Nilotinib—Vision blurred—Epirubicin—testicular cancer	4.62e-05	0.000343	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—testicular cancer	4.6e-05	0.000342	CcSEcCtD
Nilotinib—LCK—Signaling by EGFR in Cancer—KIT—testicular cancer	4.58e-05	0.000584	CbGpPWpGaD
Nilotinib—Cough—Methotrexate—testicular cancer	4.57e-05	0.000339	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—testicular cancer	4.56e-05	0.000339	CcSEcCtD
Nilotinib—CA14—Metabolism—STK11—testicular cancer	4.56e-05	0.000581	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—KIT—testicular cancer	4.56e-05	0.000581	CbGpPWpGaD
Nilotinib—Ill-defined disorder—Epirubicin—testicular cancer	4.54e-05	0.000338	CcSEcCtD
Nilotinib—Vomiting—Etoposide—testicular cancer	4.53e-05	0.000337	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—testicular cancer	4.53e-05	0.000337	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—testicular cancer	4.53e-05	0.000337	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—testicular cancer	4.53e-05	0.000336	CcSEcCtD
Nilotinib—Rash—Etoposide—testicular cancer	4.5e-05	0.000334	CcSEcCtD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	4.49e-05	0.000573	CbGpPWpGaD
Nilotinib—Dermatitis—Etoposide—testicular cancer	4.49e-05	0.000334	CcSEcCtD
Nilotinib—Headache—Etoposide—testicular cancer	4.47e-05	0.000332	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—testicular cancer	4.47e-05	0.000332	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—testicular cancer	4.46e-05	0.000331	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—testicular cancer	4.46e-05	0.000331	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—testicular cancer	4.46e-05	0.000331	CcSEcCtD
Nilotinib—CA6—Metabolism—STK11—testicular cancer	4.44e-05	0.000566	CbGpPWpGaD
Nilotinib—Dysgeusia—Doxorubicin—testicular cancer	4.44e-05	0.00033	CcSEcCtD
Nilotinib—HCK—Innate Immune System—FGFR3—testicular cancer	4.43e-05	0.000564	CbGpPWpGaD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.42e-05	0.000329	CcSEcCtD
Nilotinib—Malaise—Epirubicin—testicular cancer	4.42e-05	0.000328	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—testicular cancer	4.4e-05	0.000327	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—testicular cancer	4.4e-05	0.000327	CcSEcCtD
Nilotinib—LCK—Innate Immune System—BCL10—testicular cancer	4.4e-05	0.000561	CbGpPWpGaD
Nilotinib—Syncope—Epirubicin—testicular cancer	4.39e-05	0.000326	CcSEcCtD
Nilotinib—PDGFRA—Signaling by NGF—KIT—testicular cancer	4.39e-05	0.00056	CbGpPWpGaD
Nilotinib—Leukopenia—Epirubicin—testicular cancer	4.38e-05	0.000326	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—testicular cancer	4.38e-05	0.000326	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—testicular cancer	4.36e-05	0.000324	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—testicular cancer	4.33e-05	0.000322	CcSEcCtD
Nilotinib—LCK—B Cell Activation—KIT—testicular cancer	4.31e-05	0.00055	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—FGFR3—testicular cancer	4.31e-05	0.000549	CbGpPWpGaD
Nilotinib—Confusional state—Methotrexate—testicular cancer	4.31e-05	0.00032	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—testicular cancer	4.3e-05	0.00032	CcSEcCtD
Nilotinib—MAPK11—Innate Immune System—KITLG—testicular cancer	4.3e-05	0.000548	CbGpPWpGaD
Nilotinib—Cough—Epirubicin—testicular cancer	4.27e-05	0.000318	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—testicular cancer	4.27e-05	0.000317	CcSEcCtD
Nilotinib—Infection—Methotrexate—testicular cancer	4.24e-05	0.000315	CcSEcCtD
Nilotinib—Nausea—Etoposide—testicular cancer	4.24e-05	0.000315	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—testicular cancer	4.23e-05	0.000314	CcSEcCtD
Nilotinib—PDGFRB—Signaling Pathways—INSL3—testicular cancer	4.23e-05	0.000539	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—BCL10—testicular cancer	4.22e-05	0.000539	CbGpPWpGaD
Nilotinib—CA4—Metabolism—HPGDS—testicular cancer	4.22e-05	0.000538	CbGpPWpGaD
Nilotinib—Ill-defined disorder—Doxorubicin—testicular cancer	4.2e-05	0.000312	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—testicular cancer	4.19e-05	0.000311	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—testicular cancer	4.19e-05	0.000311	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—testicular cancer	4.18e-05	0.000311	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—testicular cancer	4.17e-05	0.00031	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—testicular cancer	4.17e-05	0.00031	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—testicular cancer	4.17e-05	0.00031	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—testicular cancer	4.15e-05	0.000309	CcSEcCtD
Nilotinib—MAPK11—Immune System—BCL10—testicular cancer	4.15e-05	0.00053	CbGpPWpGaD
Nilotinib—Skin disorder—Methotrexate—testicular cancer	4.15e-05	0.000308	CcSEcCtD
Nilotinib—CA7—Metabolism—STK11—testicular cancer	4.15e-05	0.000529	CbGpPWpGaD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.14e-05	0.000308	CcSEcCtD
Nilotinib—LYN—Signaling Pathways—INSL3—testicular cancer	4.14e-05	0.000528	CbGpPWpGaD
Nilotinib—Hyperhidrosis—Methotrexate—testicular cancer	4.13e-05	0.000307	CcSEcCtD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	4.13e-05	0.000526	CbGpPWpGaD
Nilotinib—Discomfort—Epirubicin—testicular cancer	4.12e-05	0.000306	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—testicular cancer	4.09e-05	0.000304	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—testicular cancer	4.08e-05	0.000303	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—testicular cancer	4.07e-05	0.000303	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—testicular cancer	4.07e-05	0.000303	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—testicular cancer	4.06e-05	0.000302	CcSEcCtD
Nilotinib—HCK—Innate Immune System—KIT—testicular cancer	4.06e-05	0.000518	CbGpPWpGaD
Nilotinib—Leukopenia—Doxorubicin—testicular cancer	4.06e-05	0.000301	CcSEcCtD
Nilotinib—CA2—Metabolism—HPGDS—testicular cancer	4.04e-05	0.000515	CbGpPWpGaD
Nilotinib—Confusional state—Epirubicin—testicular cancer	4.03e-05	0.000299	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—FGFR3—testicular cancer	4.01e-05	0.000511	CbGpPWpGaD
Nilotinib—Palpitations—Doxorubicin—testicular cancer	4e-05	0.000298	CcSEcCtD
Nilotinib—MAPK14—Signaling by NGF—FGFR3—testicular cancer	4e-05	0.00051	CbGpPWpGaD
Nilotinib—Oedema—Epirubicin—testicular cancer	4e-05	0.000297	CcSEcCtD
Nilotinib—FGR—Innate Immune System—FGFR3—testicular cancer	4e-05	0.00051	CbGpPWpGaD
Nilotinib—Hypotension—Methotrexate—testicular cancer	3.99e-05	0.000297	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—testicular cancer	3.98e-05	0.000296	CcSEcCtD
Nilotinib—Infection—Epirubicin—testicular cancer	3.97e-05	0.000295	CcSEcCtD
Nilotinib—PDGFRB—Signaling by NGF—KIT—testicular cancer	3.95e-05	0.000504	CbGpPWpGaD
Nilotinib—Cough—Doxorubicin—testicular cancer	3.95e-05	0.000294	CcSEcCtD
Nilotinib—Shock—Epirubicin—testicular cancer	3.93e-05	0.000292	CcSEcCtD
Nilotinib—MAPK14—Signaling Pathways—INSL3—testicular cancer	3.92e-05	0.0005	CbGpPWpGaD
Nilotinib—Nervous system disorder—Epirubicin—testicular cancer	3.92e-05	0.000291	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—testicular cancer	3.91e-05	0.000291	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—testicular cancer	3.91e-05	0.000291	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—testicular cancer	3.9e-05	0.00029	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.89e-05	0.000289	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—testicular cancer	3.88e-05	0.000289	CcSEcCtD
Nilotinib—KIT—Innate Immune System—KITLG—testicular cancer	3.88e-05	0.000494	CbGpPWpGaD
Nilotinib—CA1—Metabolism—HPGDS—testicular cancer	3.87e-05	0.000494	CbGpPWpGaD
Nilotinib—Hyperhidrosis—Epirubicin—testicular cancer	3.86e-05	0.000287	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—testicular cancer	3.86e-05	0.000287	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—testicular cancer	3.86e-05	0.000287	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—testicular cancer	3.86e-05	0.000287	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—testicular cancer	3.86e-05	0.000287	CcSEcCtD
Nilotinib—BLK—Adaptive Immune System—FGFR3—testicular cancer	3.85e-05	0.000491	CbGpPWpGaD
Nilotinib—Anxiety—Doxorubicin—testicular cancer	3.84e-05	0.000286	CcSEcCtD
Nilotinib—CA12—Metabolism—STK11—testicular cancer	3.84e-05	0.00049	CbGpPWpGaD
Nilotinib—Paraesthesia—Methotrexate—testicular cancer	3.84e-05	0.000285	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.83e-05	0.000285	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—testicular cancer	3.81e-05	0.000283	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—testicular cancer	3.81e-05	0.000283	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—testicular cancer	3.81e-05	0.000283	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—testicular cancer	3.77e-05	0.00028	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—testicular cancer	3.76e-05	0.000279	CcSEcCtD
Nilotinib—KIT—Immune System—BCL10—testicular cancer	3.74e-05	0.000478	CbGpPWpGaD
Nilotinib—Hypotension—Epirubicin—testicular cancer	3.73e-05	0.000278	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—testicular cancer	3.73e-05	0.000277	CcSEcCtD
Nilotinib—KIT—Adaptive Immune System—KITLG—testicular cancer	3.72e-05	0.000475	CbGpPWpGaD
Nilotinib—Decreased appetite—Methotrexate—testicular cancer	3.71e-05	0.000276	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—testicular cancer	3.7e-05	0.000275	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—testicular cancer	3.69e-05	0.000274	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—testicular cancer	3.68e-05	0.000274	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—KIT—testicular cancer	3.68e-05	0.00047	CbGpPWpGaD
Nilotinib—Infection—Doxorubicin—testicular cancer	3.67e-05	0.000273	CcSEcCtD
Nilotinib—MAPK14—Signaling by NGF—KIT—testicular cancer	3.67e-05	0.000468	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—KITLG—testicular cancer	3.67e-05	0.000468	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—KIT—testicular cancer	3.67e-05	0.000468	CbGpPWpGaD
Nilotinib—Pain—Methotrexate—testicular cancer	3.65e-05	0.000271	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	3.64e-05	0.000271	CcSEcCtD
Nilotinib—Shock—Doxorubicin—testicular cancer	3.64e-05	0.00027	CcSEcCtD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.64e-05	0.000464	CbGpPWpGaD
Nilotinib—Nervous system disorder—Doxorubicin—testicular cancer	3.63e-05	0.00027	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—testicular cancer	3.62e-05	0.000269	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—testicular cancer	3.61e-05	0.000269	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—testicular cancer	3.61e-05	0.000268	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—testicular cancer	3.59e-05	0.000267	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—testicular cancer	3.59e-05	0.000267	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—testicular cancer	3.58e-05	0.000266	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—testicular cancer	3.56e-05	0.000265	CcSEcCtD
Nilotinib—PDGFRA—Immune System—BCL10—testicular cancer	3.54e-05	0.000452	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—KIT—testicular cancer	3.54e-05	0.000451	CbGpPWpGaD
Nilotinib—Anorexia—Doxorubicin—testicular cancer	3.53e-05	0.000262	CcSEcCtD
Nilotinib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	3.52e-05	0.000449	CbGpPWpGaD
Nilotinib—Feeling abnormal—Methotrexate—testicular cancer	3.52e-05	0.000262	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—testicular cancer	3.52e-05	0.000261	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—testicular cancer	3.49e-05	0.00026	CcSEcCtD
Nilotinib—HCK—Disease—H2AFZ—testicular cancer	3.48e-05	0.000444	CbGpPWpGaD
Nilotinib—Decreased appetite—Epirubicin—testicular cancer	3.47e-05	0.000258	CcSEcCtD
Nilotinib—HCK—Immune System—KITLG—testicular cancer	3.47e-05	0.000442	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—FGFR3—testicular cancer	3.46e-05	0.000441	CbGpPWpGaD
Nilotinib—Hypotension—Doxorubicin—testicular cancer	3.46e-05	0.000257	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—testicular cancer	3.45e-05	0.000256	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—testicular cancer	3.45e-05	0.000256	CcSEcCtD
Nilotinib—Constipation—Epirubicin—testicular cancer	3.42e-05	0.000254	CcSEcCtD
Nilotinib—Pain—Epirubicin—testicular cancer	3.42e-05	0.000254	CcSEcCtD
Nilotinib—CA9—Metabolism—HPGDS—testicular cancer	3.41e-05	0.000434	CbGpPWpGaD
Nilotinib—Urticaria—Methotrexate—testicular cancer	3.39e-05	0.000252	CcSEcCtD
Nilotinib—LCK—Signaling Pathways—INSL3—testicular cancer	3.39e-05	0.000433	CbGpPWpGaD
Nilotinib—Body temperature increased—Methotrexate—testicular cancer	3.38e-05	0.000251	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—testicular cancer	3.38e-05	0.000251	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.37e-05	0.00025	CcSEcCtD
Nilotinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.35e-05	0.000428	CbGpPWpGaD
Nilotinib—Insomnia—Doxorubicin—testicular cancer	3.34e-05	0.000249	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—testicular cancer	3.32e-05	0.000247	CcSEcCtD
Nilotinib—PDGFRB—Innate Immune System—KITLG—testicular cancer	3.31e-05	0.000422	CbGpPWpGaD
Nilotinib—Dyspnoea—Doxorubicin—testicular cancer	3.3e-05	0.000245	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—testicular cancer	3.29e-05	0.000245	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—testicular cancer	3.27e-05	0.000243	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—testicular cancer	3.26e-05	0.000242	CcSEcCtD
Nilotinib—LYN—Innate Immune System—KITLG—testicular cancer	3.24e-05	0.000413	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KITLG—testicular cancer	3.22e-05	0.000411	CbGpPWpGaD
Nilotinib—Decreased appetite—Doxorubicin—testicular cancer	3.21e-05	0.000239	CcSEcCtD
Nilotinib—HCK—Disease—KITLG—testicular cancer	3.2e-05	0.000408	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—FGFR3—testicular cancer	3.19e-05	0.000407	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BCL10—testicular cancer	3.19e-05	0.000407	CbGpPWpGaD
Nilotinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.19e-05	0.000237	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—testicular cancer	3.19e-05	0.000237	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—testicular cancer	3.18e-05	0.000236	CcSEcCtD
Nilotinib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	3.17e-05	0.000405	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—KIT—testicular cancer	3.17e-05	0.000405	CbGpPWpGaD
Nilotinib—Constipation—Doxorubicin—testicular cancer	3.16e-05	0.000235	CcSEcCtD
Nilotinib—Pain—Doxorubicin—testicular cancer	3.16e-05	0.000235	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—testicular cancer	3.16e-05	0.000235	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—testicular cancer	3.16e-05	0.000235	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—testicular cancer	3.15e-05	0.000234	CcSEcCtD
Nilotinib—BLK—Immune System—KITLG—testicular cancer	3.14e-05	0.000401	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KITLG—testicular cancer	3.14e-05	0.000401	CbGpPWpGaD
Nilotinib—FGR—Immune System—KITLG—testicular cancer	3.13e-05	0.000399	CbGpPWpGaD
Nilotinib—LYN—Immune System—BCL10—testicular cancer	3.13e-05	0.000399	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BCL10—testicular cancer	3.11e-05	0.000397	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KITLG—testicular cancer	3.11e-05	0.000396	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—MMP2—testicular cancer	3.11e-05	0.000396	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—MMP2—testicular cancer	3.09e-05	0.000394	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KITLG—testicular cancer	3.07e-05	0.000391	CbGpPWpGaD
Nilotinib—Asthenia—Methotrexate—testicular cancer	3.06e-05	0.000228	CcSEcCtD
Nilotinib—CA4—Metabolism—STK11—testicular cancer	3.06e-05	0.000391	CbGpPWpGaD
Nilotinib—Feeling abnormal—Doxorubicin—testicular cancer	3.05e-05	0.000226	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—testicular cancer	3.02e-05	0.000225	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—testicular cancer	3.02e-05	0.000225	CcSEcCtD
Nilotinib—MAPK14—Immune System—BCL10—testicular cancer	2.96e-05	0.000378	CbGpPWpGaD
Nilotinib—Hypersensitivity—Epirubicin—testicular cancer	2.94e-05	0.000219	CcSEcCtD
Nilotinib—MAPK11—Developmental Biology—MMP2—testicular cancer	2.94e-05	0.000375	CbGpPWpGaD
Nilotinib—Urticaria—Doxorubicin—testicular cancer	2.94e-05	0.000218	CcSEcCtD
Nilotinib—CA2—Metabolism—STK11—testicular cancer	2.94e-05	0.000375	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—KIT—testicular cancer	2.93e-05	0.000374	CbGpPWpGaD
Nilotinib—Abdominal pain—Doxorubicin—testicular cancer	2.92e-05	0.000217	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—testicular cancer	2.92e-05	0.000217	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—testicular cancer	2.92e-05	0.000217	CcSEcCtD
Nilotinib—KIT—Innate Immune System—FGFR3—testicular cancer	2.88e-05	0.000367	CbGpPWpGaD
Nilotinib—Asthenia—Epirubicin—testicular cancer	2.87e-05	0.000213	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—testicular cancer	2.83e-05	0.00021	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—testicular cancer	2.82e-05	0.00021	CcSEcCtD
Nilotinib—CA1—Metabolism—STK11—testicular cancer	2.82e-05	0.000359	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—FGFR3—testicular cancer	2.77e-05	0.000353	CbGpPWpGaD
Nilotinib—Diarrhoea—Epirubicin—testicular cancer	2.73e-05	0.000203	CcSEcCtD
Nilotinib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	2.73e-05	0.000348	CbGpPWpGaD
Nilotinib—Hypersensitivity—Doxorubicin—testicular cancer	2.72e-05	0.000202	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—testicular cancer	2.72e-05	0.000202	CcSEcCtD
Nilotinib—MAPK11—Gene Expression—H2AFZ—testicular cancer	2.71e-05	0.000345	CbGpPWpGaD
Nilotinib—Rash—Methotrexate—testicular cancer	2.69e-05	0.0002	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—testicular cancer	2.69e-05	0.0002	CcSEcCtD
Nilotinib—Headache—Methotrexate—testicular cancer	2.68e-05	0.000199	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—testicular cancer	2.65e-05	0.000197	CcSEcCtD
Nilotinib—LCK—Innate Immune System—KITLG—testicular cancer	2.65e-05	0.000338	CbGpPWpGaD
Nilotinib—Dizziness—Epirubicin—testicular cancer	2.64e-05	0.000196	CcSEcCtD
Nilotinib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	2.62e-05	0.000334	CbGpPWpGaD
Nilotinib—Pruritus—Doxorubicin—testicular cancer	2.62e-05	0.000194	CcSEcCtD
Nilotinib—HCK—Immune System—FGFR3—testicular cancer	2.58e-05	0.000329	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL10—testicular cancer	2.56e-05	0.000327	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KITLG—testicular cancer	2.55e-05	0.000325	CbGpPWpGaD
Nilotinib—Vomiting—Epirubicin—testicular cancer	2.54e-05	0.000189	CcSEcCtD
Nilotinib—Nausea—Methotrexate—testicular cancer	2.54e-05	0.000189	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—testicular cancer	2.53e-05	0.000188	CcSEcCtD
Nilotinib—Rash—Epirubicin—testicular cancer	2.52e-05	0.000187	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—testicular cancer	2.52e-05	0.000187	CcSEcCtD
Nilotinib—Headache—Epirubicin—testicular cancer	2.5e-05	0.000186	CcSEcCtD
Nilotinib—MAPK11—Immune System—KITLG—testicular cancer	2.5e-05	0.000319	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—KIT—testicular cancer	2.5e-05	0.000319	CbGpPWpGaD
Nilotinib—BRAF—Disease—H2AFZ—testicular cancer	2.49e-05	0.000317	CbGpPWpGaD
Nilotinib—CA9—Metabolism—STK11—testicular cancer	2.47e-05	0.000316	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	2.46e-05	0.000313	CbGpPWpGaD
Nilotinib—Dizziness—Doxorubicin—testicular cancer	2.45e-05	0.000182	CcSEcCtD
Nilotinib—LYN—Innate Immune System—FGFR3—testicular cancer	2.41e-05	0.000307	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	2.4e-05	0.000307	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.4e-05	0.000306	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—FGFR3—testicular cancer	2.39e-05	0.000305	CbGpPWpGaD
Nilotinib—HCK—Disease—FGFR3—testicular cancer	2.38e-05	0.000304	CbGpPWpGaD
Nilotinib—Nausea—Epirubicin—testicular cancer	2.37e-05	0.000176	CcSEcCtD
Nilotinib—HCK—Immune System—KIT—testicular cancer	2.37e-05	0.000302	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	2.36e-05	0.000301	CbGpPWpGaD
Nilotinib—Vomiting—Doxorubicin—testicular cancer	2.35e-05	0.000175	CcSEcCtD
Nilotinib—BLK—Immune System—FGFR3—testicular cancer	2.34e-05	0.000298	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—FGFR3—testicular cancer	2.34e-05	0.000298	CbGpPWpGaD
Nilotinib—Rash—Doxorubicin—testicular cancer	2.33e-05	0.000173	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—testicular cancer	2.33e-05	0.000173	CcSEcCtD
Nilotinib—FGR—Immune System—FGFR3—testicular cancer	2.33e-05	0.000297	CbGpPWpGaD
Nilotinib—Headache—Doxorubicin—testicular cancer	2.32e-05	0.000172	CcSEcCtD
Nilotinib—LYN—Adaptive Immune System—FGFR3—testicular cancer	2.31e-05	0.000295	CbGpPWpGaD
Nilotinib—BRAF—Disease—KITLG—testicular cancer	2.29e-05	0.000292	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—FGFR3—testicular cancer	2.28e-05	0.000291	CbGpPWpGaD
Nilotinib—KIT—Disease—H2AFZ—testicular cancer	2.27e-05	0.000289	CbGpPWpGaD
Nilotinib—KIT—Immune System—KITLG—testicular cancer	2.26e-05	0.000288	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—KIT—testicular cancer	2.26e-05	0.000288	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP2—testicular cancer	2.22e-05	0.000283	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—H2AFZ—testicular cancer	2.21e-05	0.000282	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—KIT—testicular cancer	2.21e-05	0.000282	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP2—testicular cancer	2.21e-05	0.000281	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KIT—testicular cancer	2.2e-05	0.00028	CbGpPWpGaD
Nilotinib—Nausea—Doxorubicin—testicular cancer	2.2e-05	0.000163	CcSEcCtD
Nilotinib—MAPK8—Signaling Pathways—STK11—testicular cancer	2.2e-05	0.00028	CbGpPWpGaD
Nilotinib—HCK—Disease—KIT—testicular cancer	2.18e-05	0.000279	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	2.17e-05	0.000276	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—H2AFZ—testicular cancer	2.14e-05	0.000274	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KIT—testicular cancer	2.14e-05	0.000273	CbGpPWpGaD
Nilotinib—BLK—Immune System—KIT—testicular cancer	2.14e-05	0.000273	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KITLG—testicular cancer	2.14e-05	0.000273	CbGpPWpGaD
Nilotinib—FGR—Immune System—KIT—testicular cancer	2.14e-05	0.000273	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KIT—testicular cancer	2.12e-05	0.00027	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP2—testicular cancer	2.1e-05	0.000268	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	2.1e-05	0.000268	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KIT—testicular cancer	2.09e-05	0.000267	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	2.09e-05	0.000266	CbGpPWpGaD
Nilotinib—KIT—Disease—KITLG—testicular cancer	2.08e-05	0.000266	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KITLG—testicular cancer	2.03e-05	0.000259	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—HPGDS—testicular cancer	2.03e-05	0.000259	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KITLG—testicular cancer	1.97e-05	0.000252	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FGFR3—testicular cancer	1.97e-05	0.000251	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.95e-05	0.000249	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—H2AFZ—testicular cancer	1.93e-05	0.000246	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	1.93e-05	0.000246	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—H2AFZ—testicular cancer	1.93e-05	0.000246	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KITLG—testicular cancer	1.93e-05	0.000246	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.89e-05	0.000241	CbGpPWpGaD
Nilotinib—LYN—Immune System—KITLG—testicular cancer	1.89e-05	0.00024	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KITLG—testicular cancer	1.88e-05	0.000239	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FGFR3—testicular cancer	1.86e-05	0.000237	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KIT—testicular cancer	1.81e-05	0.000231	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KITLG—testicular cancer	1.79e-05	0.000228	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KITLG—testicular cancer	1.78e-05	0.000227	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—H2AFZ—testicular cancer	1.76e-05	0.000224	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STK11—testicular cancer	1.75e-05	0.000223	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—H2AFZ—testicular cancer	1.74e-05	0.000222	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KIT—testicular cancer	1.74e-05	0.000222	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STK11—testicular cancer	1.73e-05	0.000221	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—HPGDS—testicular cancer	1.72e-05	0.00022	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KIT—testicular cancer	1.71e-05	0.000218	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGFR3—testicular cancer	1.7e-05	0.000217	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGFR3—testicular cancer	1.68e-05	0.000214	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KITLG—testicular cancer	1.62e-05	0.000206	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KITLG—testicular cancer	1.6e-05	0.000205	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGFR3—testicular cancer	1.59e-05	0.000203	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—H2AFZ—testicular cancer	1.59e-05	0.000202	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STK11—testicular cancer	1.58e-05	0.000201	CbGpPWpGaD
Nilotinib—BRAF—Disease—KIT—testicular cancer	1.56e-05	0.000199	CbGpPWpGaD
Nilotinib—LCK—Disease—H2AFZ—testicular cancer	1.55e-05	0.000198	CbGpPWpGaD
Nilotinib—KIT—Disease—FGFR3—testicular cancer	1.55e-05	0.000198	CbGpPWpGaD
Nilotinib—LCK—Immune System—KITLG—testicular cancer	1.55e-05	0.000197	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGFR3—testicular cancer	1.51e-05	0.000193	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	1.5e-05	0.000192	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STK11—testicular cancer	1.49e-05	0.00019	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—STK11—testicular cancer	1.47e-05	0.000188	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR3—testicular cancer	1.47e-05	0.000187	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KITLG—testicular cancer	1.46e-05	0.000186	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KIT—testicular cancer	1.46e-05	0.000186	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	1.44e-05	0.000183	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR3—testicular cancer	1.43e-05	0.000183	CbGpPWpGaD
Nilotinib—LCK—Disease—KITLG—testicular cancer	1.43e-05	0.000182	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR3—testicular cancer	1.4e-05	0.000179	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR3—testicular cancer	1.39e-05	0.000178	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KIT—testicular cancer	1.39e-05	0.000177	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	1.38e-05	0.000176	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	1.35e-05	0.000173	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KIT—testicular cancer	1.35e-05	0.000172	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STK11—testicular cancer	1.35e-05	0.000172	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR3—testicular cancer	1.33e-05	0.000169	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—H2AFZ—testicular cancer	1.32e-05	0.000169	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR3—testicular cancer	1.32e-05	0.000169	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	1.32e-05	0.000168	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STK11—testicular cancer	1.32e-05	0.000168	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KIT—testicular cancer	1.31e-05	0.000168	CbGpPWpGaD
Nilotinib—LYN—Immune System—KIT—testicular cancer	1.29e-05	0.000164	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KIT—testicular cancer	1.28e-05	0.000163	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HPGDS—testicular cancer	1.26e-05	0.000161	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—H2AFZ—testicular cancer	1.26e-05	0.00016	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—STK11—testicular cancer	1.25e-05	0.00016	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STK11—testicular cancer	1.25e-05	0.000159	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	1.24e-05	0.000159	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KIT—testicular cancer	1.22e-05	0.000156	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KITLG—testicular cancer	1.22e-05	0.000155	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KIT—testicular cancer	1.21e-05	0.000155	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR3—testicular cancer	1.2e-05	0.000153	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR3—testicular cancer	1.19e-05	0.000152	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KITLG—testicular cancer	1.16e-05	0.000147	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR3—testicular cancer	1.15e-05	0.000146	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KIT—testicular cancer	1.1e-05	0.000141	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KIT—testicular cancer	1.09e-05	0.00014	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	1.09e-05	0.000138	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR3—testicular cancer	1.08e-05	0.000138	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STK11—testicular cancer	1.08e-05	0.000138	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HPGDS—testicular cancer	1.07e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR3—testicular cancer	1.06e-05	0.000135	CbGpPWpGaD
Nilotinib—LCK—Immune System—KIT—testicular cancer	1.05e-05	0.000134	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	1.03e-05	0.000131	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KITLG—testicular cancer	9.99e-06	0.000127	CbGpPWpGaD
Nilotinib—LCK—Disease—KIT—testicular cancer	9.73e-06	0.000124	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KIT—testicular cancer	9.43e-06	0.00012	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HPGDS—testicular cancer	9.31e-06	0.000119	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	9.25e-06	0.000118	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—STK11—testicular cancer	9.17e-06	0.000117	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR3—testicular cancer	9.06e-06	0.000116	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HPGDS—testicular cancer	8.77e-06	0.000112	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HPGDS—testicular cancer	8.69e-06	0.000111	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR3—testicular cancer	8.59e-06	0.00011	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—testicular cancer	8.49e-06	0.000108	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—testicular cancer	8.32e-06	0.000106	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—testicular cancer	7.88e-06	0.000101	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—STK11—testicular cancer	7.76e-06	9.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR3—testicular cancer	7.42e-06	9.47e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—testicular cancer	6.82e-06	8.69e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—STK11—testicular cancer	6.76e-06	8.63e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—STK11—testicular cancer	6.37e-06	8.13e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—STK11—testicular cancer	6.32e-06	8.06e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HPGDS—testicular cancer	5.73e-06	7.31e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—testicular cancer	4.17e-06	5.31e-05	CbGpPWpGaD
